Clermont Ferrand cedex 01, France Clinical Trials

A listing of Clermont Ferrand cedex 01, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 9 clinical trials
An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma

The overall aim of this project is to improve the outcome of patients diagnosed with ependymoma by improving and harmonising the staging and the standard of care of this patient population and to improve the investigators understanding of the underlying biology thereby informing future treatment. The program will evaluate new …

CHU Clermont- Ferrand - H pital Estaing
 (2.1 away) Contact site
  • 25 views
  • 24 Jan, 2021
  • +61 other locations
Evaluation of a Marine OXYgen Carrier for Organ Preservation

Preventing ischemia/reperfusion injuries (IRIs) is a major issue in kidney transplantation, particularly for transplant recipients receiving a kidney from extended criteria donors (ECD). The main consequence of IRIs is delayed graft function (DGF). The medical device HEMO2life, an oxygen carrier developed by the Hemarina French Company, is a natural extracellular …

Saint-Etienne
 (66.8 away) Contact site
  • 0 views
  • 24 Jan, 2021
  • +21 other locations
Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome

This protocol includes 2 independent studies. Both studies are multicenter studies, evaluating different therapeutic approaches in two different populations of patients: Study 1, a randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments. Study 2, a …

CHU ESTAING Centre R gional de Canc rologie et Therapie Cellulaire Pediatrique (CRCTCP)
 (2.1 away) Contact site
  • 0 views
  • 13 Apr, 2021
  • +27 other locations
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The primary hypotheses are: Olaparib plus pembrolizumab prolongs progression-free survival (PFS) compared with chemotherapy plus pembrolizumab. Olaparib …

carboplatin
breast cancer
cancer
pembrolizumab
measurable disease
Centre Jean Perrin ( Site 1003)
 (1.3 away) Contact site
  • 241 views
  • 10 Jun, 2021
  • +131 other locations
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than 5% bone marrow blasts, no blasts in cerebrospinal fluid, no other extramedullary leukemia), who have an indication …

transplant conditioning
cancer
thiotepa
cyclophosphamide
fludarabine
IHOP / Lyon, Service H matologie et d'Oncologie p diatrique
 (84.0 away) Contact site
  • 389 views
  • 25 Jan, 2021
  • +157 other locations
Study to Improve OS in 18 to 60 Year-old Patients Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategies. Within the intermediate risk AML group, optimal GvHD prophylaxis following …

mycophenolate mofetil
cancer
induction chemotherapy
granulocyte colony stimulating factor
filgrastim
Institut de Canc rologie Lucien Neuwirth
 (65.6 away) Contact site
  • 42 views
  • 25 Jan, 2021
  • +56 other locations
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.

crohn's disease
ustekinumab
ileitis
colitis
endoscopy
CHU Clermont-Ferrant-Hopital Hotel Dieu
 (1.6 away) Contact site
  • 792 views
  • 13 Jun, 2021
  • +795 other locations
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib

Carcinosarcomas (CS) (malignant mixed Mllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e. ovarian CS (OCS) and uterine CS (UCS), have a 5-year overall survival (OS) < 10% and a poor prognosis. After initial treatment (surgery +/- adjuvant radiotherapies …

Centre Jean Perrin
 (1.6 away) Contact site
  • 0 views
  • 25 Jan, 2021
  • +18 other locations
Effects of PR Oxycodone and of Levodopa vs Placebo on Central Neuropathic Pain in Parkinson's Disease

This study will be conducted in three parallel groups receiving oxycodone, levodopa or placebo, administered as an add-on therapy, in addition to the usual antiparkinsonian treatment. As this study focuses on chronic central neuropathic pain caused by PD, the effects of study treatments will be evaluated after a 10-week treatment …

dopamine
dopamine agonists
levodopa
antiparkinsonian agents
antidepressants
University Hospital of Limoges
 (76.3 away) Contact site
  • 18 views
  • 26 Jan, 2021
  • +17 other locations